Long-term effects of weight-reducing drugs in people with hypertension

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Siebenhofer, Andrea ^a,b   Jeitler, Klaus ^b   Horvath, Karl ^b   Berghold, Andrea ^b   Posch, Nicole ^b   Meschik, Jutta ^b   Semlitsch, Thomas ^b  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIOBESITY AGENT; LIRAGLUTIDE; LORCASERIN; NALTREXONE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; FRUCTOSE; LACTONE; PHENTERMINE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TOPIRAMATE;

ARTHRALGIA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COMPARATIVE STUDY; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; HEADACHE; HUMAN; HYPERTENSION; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY (TOPIC); PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA; ADULT; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DRUG EFFECTS; DRUG RECALL; FEMALE; LOW CALORY DIET; MALE; MIDDLE AGED; MORTALITY; TIME;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BLOOD PRESSURE; CYCLOBUTANES; DIET, REDUCING; FEMALE; FRUCTOSE; HUMANS; HYPERTENSION; LACTONES; MALE; MIDDLE AGED; PHENTERMINE; PIPERIDINES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFETY-BASED DRUG WITHDRAWALS; TIME; WEIGHT LOSS;

EID: 84961875595     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007654.pub4     Document Type: Review

References (196)

1. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension 2002;20(11):2257-67.
2. Cocco G, Pandolfi S, Rousson V. Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: A randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise). Heart Drug 2005;5(2):68-74.
3. Astrup AV, Oppert JM, Peterson CA. Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes. Diabetologia 2012;55(Suppl1):S284-S285. [EMBASE: 70888716]
4. Cheskin J, Bowden CH. Reduction of cardiovascular risk factors by magnitude of weight loss in obese and overweight subjects with >2 comorbidities. Journal of General Internal Medicine 2013;28(Suppl1):S168. [EMBASE: 71292986]
5. Cheskin LJ, Peterson CA. Improved cardiometabolic risk factors in overweight/obese subjects receiving controlled-release phentermine/topiramate (PHEN/TPM CR). Diabetes 2012;61(Suppl1):A710. [EMBASE: 70799295]
6. Davidson M, Bowden CH, Day WW. Weight loss and cardiovascular risk reduction over 2 years with controlled-release phentermine-topiramate. Journal of the American College of Cardiology 2011;57(14, Supplement):E545. [EMBASE: 70400222]
7. Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index >27 kg/m(2). American Journal of Cardiology 2013;111(8):1131-8. [PUBMED: 23375187]
8. Finer N, Jordan J, Dvorak R. Weight loss and improvements in blood pressure (BP) status associated with phentermine and topiramate extended-release (PHEN/TPM ER) treatment in obese and overweight adults. Obesity Facts 2013;6(Suppl1):45. [EMBASE: 71300090]
9. Gadde K, Najarian T, Day WW. Magnitude of weight loss experienced with a low-dose, controlled-release formulation of phentermine/topiramate (PHEN/TPM) may drive degree of cardiometabolic benefit. Diabetes 2010;Conference Publication:(var. pagings). [EMBASE: 71602039]
10. Gadde K, Peterson C, Troupin B, Day WW. 12-month weight loss and antihypertensive benefits with PHEN/TPM in overweight and obese subjects with hypertension. European Journal of Cardiovascular Prevention and Rehabilitation 2010;17(2 Suppl):S2. [EMBASE: 70349685]
11. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.[Erratum appears in Lancet. 2011 Apr 30;377(9776):1494]. The Lancet 2011;377(9774):1341-52. [PUBMED: 21481449]
12. Gadde KM, Day WW. Low-dose, controlled-release phentermine/topiramate for reduction of weight, related risks in overweight/obese adults with >2 comorbidities. Obesity Reviews 2010;11(Suppl1):42-3. [EMBASE: 70226591]
13. Garvey W T, Troupin B, Day W W. Once-daily, low-dose, controlled-release phentermine/topiramate results in significant clinical improvements in overweight/obese patients with type 2 diabetes. Diabetologia 2010;53(1 Supplement):S308. [EMBASE: 70262814]
14. Garvey WT, Gadde K, Tam P, Peterson C. Changes in insulin sensitivity in overweight/obese patients treated with low-dose, controlled-release phentermine/topiramate (PHEN/TPM). Diabetes 2010;Conference Publication:(var. pagings). [EMBASE: 71602034]
15. Garvey WT, Gadde K, Wilson LF, Peterson C. Improvements in dyslipidemia and other cardiometabolic disease risk factors with low-dose, controlled-release phentermine/topiramate (PHEN/TPM). Diabetes 2010;Conference Publication:(var. pagings). [EMBASE: 71601293]
16. Garvey WT, Henry R R, Peterson C A, Bowden C H. Weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) reverses metabolic syndrome (MetS) and improves associated traits. Diabetes 2011;60(Suppl1):A506. [EMBASE: 70629626]
17. Gupta AK, Church T, Day WW. Obesity treatment-induced weight loss improves resting blood pressure and reduces progression from prehypertension to hypertension in overweight/obese adults. Circulation 2013;127:(12 Meeting Abstracts). [EMBASE: 71026610]
18. Kushner RF, Varghese ST. Weight loss with phentermine and topiramate extended-release in obese and overweight subjects over 56 weeks. Journal of General Internal Medicine 2013;28(Suppl1):S241. [EMBASE: 71293155]
19. Rossner SK, Sharma AM, Troupin B, Padwal RS. Effects of extended-release phentermine/topiramate on weight loss and blood pressure in obese subjects with type 2 diabetes mellitus. Diabetologia 2012;55(Suppl1):S285. [EMBASE: 70888717]
20. Ryan DH, Garvey WT, Day WW. Achievement of composite of recommended goals in obese subjects with type 2 diabetes mellitus using extended-release phentermine/topiramate in a 56-week weight loss intervention. Endocrine Reviews 2012;33:(3 Meeting Abstracts). [EMBASE: 70832584]
21. Troupin B, Hankin C S. Low-dose controlled-release phentermine/topiramate (PHEN/TPM CR) results in significant weight loss and improves atherosclerotic biomarkers in overweight/obese patients with obesity-related comorbidities. Clinical Pharmacology and Therapeutics 2011;89(Suppl1):S39. [EMBASE: 70343842]
22. Fanghänel G, Cortinas L, Sanchez-Reyes L, Gomez-Santos R, Campos-Franco E, Berber A. Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Advances in Therapy 2003;20(2):101-13.
23. Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea F Sr, Zanella MT. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes, Obesity & Metabolism 2005;7(3):246-53.
24. Faria AN, Ribeiro Filho FF, Lerario DDG, Kohlmann N, Gouvea Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. [Portuguese, English]. Arquivos Brasileiros de Cardiologia 2002;78(2):172-80.
25. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes, Obesity & Metabolism 2004;6(5):375-83.
26. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Archives of Internal Medicine 2000;160(14):2185-91.
27. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. Journal of Human Hypertension 2002;16(1):5-11.
28. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. http://iqwig.de/download/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
29. Torgerson JS, Arlinger K, Kappi M, Sjostrom L. Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Controlled Clinical Trials 2001;22(5):515-25.
30. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27(1):155-61.
31. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. American Journal of Medicine 1999;106(2):179-84. [PUBMED: 10230747]
32. Bach DS, Rissanen AM, Mendel CM, Shepherd G, Weinstein SP, Kelly F, et al. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obesity Research 1999;7(4):363-9.
33. Bain SC, Ahmann A, Rodbard H, W.Rosenstock J, Lahtela J, De Loredo L, et al. A randomised, placebo-controlled trial of liraglutide as adjunct to basal insulin analogues in subjects with Type 2 diabetes (LIRA-ADD2BASAL). Diabetic Medicine 2015;32(Suppl1):71. [EMBASE: 71821007]
34. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. The New England Journal of Medicine 2010;363(3):245-56. [PUBMED: 20647200]
35. Smith SR, Weissman NJ, Stubbe S, Anderson CM, Shanahan WR. Lorcaserin reduces body weight in obese and overweight subjects: Behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial. Diabetes 2009;58:LB24. [EMBASE: 70134408]
36. Fidler MC, Shazer R, Sanchez, M, Stubbe S, Anderson CM, Shanahan WR. Lorcaserin, a selective 5-HT2C agonist, evaluated as a weight loss agent in obese and overweight patients with type 2 diabetes treated with sulfonylureas or metformin. Diabetes 2011; Vol. 60:A515. [EMBASE: 70629658]
37. O'Neil PM, Fidler MC, Sanchez, M, Weissman NJ, Smith SR, Anderson CM, et al. Randomized, placebo-controlled trial of lorcaserin for weight loss in patients with type 2 diabetes. Diabetes 2011; Vol. 60:A507. [EMBASE: 70629629]
38. O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012; Vol. 20, issue 7:1426-36. [PUBMED: 22421927]
39. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obesity Research 1999;7(2):189-98.
40. Broom I, Wilding J, Stott P, Myers N, UK Multimorbidity Study Group. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. International Journal of Clinical Practice 2002;56(7):494-9.
41. O'Neil PM, Wadden TA, Foreyt JP, Clapper B, Burns C, Klassen P, et al. Naltrexone SR/bupropion SR and intensive behavioral modification combination increases the likelihood of achieving early and sustained weight loss and associated improvement in markers of cardiometabolic risk. Obesity 2011;19(Suppl1):S179-80. [EMBASE: 70680332]
42. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity 2011;19(1):110-20. [EMBASE: 2011434989]
43. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bay H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022-9. [EMBASE: 2014021906]
44. Fujioka K, Billes SK, Burns C, Harris-Collazo R, Kim DD, Dunayevich E, et al. Weight loss and improvements in markers of metabolic risk in overweight and obese subjects completing 56 weeks of treatment with naltrexone SR/bupropion SR. Diabetes 2011;60:A520-1. [EMBASE: 70629675]
45. Fujioka K, Greenway FL, Rubino D, Clapper B, Burns C, Klassen P, et al. Completion of 56 weeks of naltrexone SR/bupropion SR combination therapy increases likelihood of achieving improvements in markers of cardiometabolic risk associated with clinically meaningful weight loss. Obesity 2011;19(Suppl1):S179. [EMBASE: 70680330]
46. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2010;376:595-605. [PUBMED: 20673995]
47. Plutzky J, Buse J, Chilton R, Mignon L, Burns C, Harris-Collazo R, et al. Response to NB at week 16 is a good predictor of significant week 56 weight loss and improvements in weight-related risk factors. Diabetes 2011;60:A700. [EMBASE: 70630321]
48. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity 2013;21(5):935-43. [PUBMED: 23408728]
49. Hill JO, Wyatt H, Billes SK, Burns C, Harris-Collazo R, Dunayevich E, et al. Naltrexone SR/bupropion SR combination therapy improves control of eating and reduces food cravings in overweight and obese subjects. Diabetes 2011;60:A506. [EMBASE: 70629625]
50. Kolotkin RL, Still C, Maier H, Burns C, Harris-Collazo R, Dunayevich E, et al. Naltrexone SR/bupropion SR combination therapy reduced weight and improved weight-related quality of life and physical health in overweight and obese subjects. Diabetes 2011;60:A506-7. [EMBASE: 70629628]
51. Plutzky J, Chilton R, Still C, Burns C, Kim D, Dunayevich E. Weight loss, blood pressure, pulse and circadian patterns with naltrexone sustained-release/bupropion sustained-release combination therapy for obesity. Journal of the American College of Cardiology 2011;57(14, Supplement):E517. [EMBASE: 70400194]
52. Rubino D, Apovian C, Mignon L, Burns C, Harris-Collazo R, Kim D. Effects of naltrexone SR/bupropion SR on weight and obesity-related health risks in overweight/obese women from the COR-II trial. Diabetes 2011;60:A504. [EMBASE: 70629619]
53. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial [see comment] [erratum appears in JAMA 1999 Apr 7;281(13):1174]. JAMA 1999;281(3):235-42.
54. de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, et al. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. Revista Portuguesa de Cardiologia 2009;28(12):1361-74.
55. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clinical Therapeutics 2003;25(4):1107-22.
56. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism: Clinical & Experimental 2008;57(11):1552-7.
57. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, et al. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. Journal of Pharmacy and Pharmaceutical Sciences 2010;13(3):378-90.
58. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, et al. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. Journal of Clinical Pharmacy and Therapeutics 2011;36(5):592-601.
59. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. The New England Journal of Medicine 2005;353(20):2121-34.
60. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arteriosclerosis, Thrombosis, and Vascular Biology 2009;29(3):416-23.
61. Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. American Heart Journal 2001;142(3):489-97.
62. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2012;20(2):330-42. [PUBMED: 22051941]
63. Erdmann J, Lippl F, Klose G, Schusdziarra V. Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations. Alimentary Pharmacology and Therapeutics 2004;19(11):1173-9.
64. Fanghänel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(2):144-50.
65. Fanghänel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2001;25(5):741-7.
66. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2000;24(3):306-13.
67. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 2000;2(3):175-87.
68. Garvey WT, Troupin B, Peterson C, Najarian T, Tam P, Day W. Treatment with VI-0521 (phentermine and topiramate) leads to one year durable glycaemic benefit and weight loss in subjects with type 2 diabetes. Diabetologia 2009;52(S1):S77. [EMBASE: 70067664]
69. Garvey WT, Troupin B, Tam P, Najarian T, Peterson C, Day WW. One-year treatment with VI-0521 in type 2 diabetes demonstrates continued glycemic improvement and weight loss. Diabetes 2009;58(Suppl. 1):A95. [EMBASE: 70136156]
70. Gentile S, Guarina G, Padovano B, Buonocunto F, Gruppo Campano Obesita. Efficacy and safety of a short-time orlistat treatment in obese subjects. [Italian] [Efficacia e sicurezza di impiego di un trattamento a breve termine con orlistat in soggetti obesi]. Annali Italiani di Medicina Interna 2005;20(2):90-6.
71. Ginsberg DL. Add-on sibutramine for olanzapine-induced weight gain. Primary Psychiatry 2004;11(7):24.
72. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. Journal of Clinical Endocrinology and Metabolism 2009;94:4898-906. [EMBASE: 2010011828]
73. Halpern A, Leite CC, Herszkowicz N, Barbato A, Costa AP. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo 2002;57(3):98-102.
74. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes, Obesity & Metabolism 2003;5(3):180-8.
75. Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, The S.A.T. Study Group. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Experimental & Clinical Endocrinology & Diabetes 2004;112(4):201-7.
76. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Archives of Family Medicine 2000;9(2):160-7.
77. Heinonen MV, Laaksonen DE, Karhu T, Karhunen L, Laitinen T, Kainulainen S, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases 2009;19(9):626-33.
78. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. American Journal of Medicine 2007;120(2 Suppl 1):S18-28.
79. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabetic Medicine 2005;22(8):1024-30.
80. Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian Journal of Endocrinology and Metabolism 2011;15(2):99-104.
81. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 1997;21 Suppl 3:S24-30.
82. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance [see comment]. The Lancet 2000;356(9248):2119-25.
83. Jia J, Xiong L, Chen S. Trial of lorcaserin for weight management. The New England Journal of Medicine 2010;363(25):2468-9. [PUBMED: 21158670]
84. Jordan J, Astrup AV, Day WW. Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors. Diabetologia 2012;55:S285. [EMBASE: 70888718]
85. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2004;28(4):600-5.
86. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial [erratum appears in Diabetes Care 2003 Mar;26(3):971]. Diabetes Care 2002;25(6):1033-41.
87. Lewis K. Weight loss achieved with medication can delay onset of type 2 diabetes in at-risk individuals. Journal of Clinical Outcomes Management 2014;21:393-5. [EMBASE: 2014910274]
88. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study [see comment]. Journal of Internal Medicine 2000;248(3):245-54.
89. Lindgarde F. Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity. Evidence-Based Medicine 2001;6(2):54.
90. Lindgarde F. Effect of orlistat on coronary heart disease risk in obese patients with hypertension and/or hyperlipidemia. American Heart Journal 2001;141(1):171.
91. Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009;58(7):946-53.
92. McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26(1):125-31.
93. Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin [erratum appears in Diabetes Care 2002 Sep;25(9):1671]. Diabetes Care 2002;25(7):1123-8.
94. Niskanen L, Astrup A, Hakim MA, Carraro R, Finer N, Hartvig H, et al. Liraglutide once daily reduces the prevalence of prediabetes and metabolic syndrome in obese non-diabetic adults: A 2-year randomized trial. Obesity 2010;18:S56. [EMBASE: 71774529]
95. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299(13):1547-60.
96. O'Leary DH, Reuwer AQ, Nissen SE, Despres JP, Deanfield JE, Brown MW, et al. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart 2011;97(14):1143-50.
97. Pathan MF, Latif ZA, Nazneen NE, Mili SU. Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. Bangladesh Medical Research Council Bulletin 2004;30(1):1-8.
98. Patschan S, Scholze J. Obesity-related hypertension. Cardiology Review 2007;24(12):32-5.
99. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial [see comment] [erratum appears in JAMA 2006 Mar 15;295(11):1252]. JAMA 2006;295(7):761-75.
100. Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. American Journal of Cardiology 2001;87(7):827-31.
101. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obesity Research 2000;8(1):49-61.
102. Rossner S. Sibutramine - antidepressive agent tested against obesity. [Swedish] [Sibutramin - antidepressivt läkemedel prövat mot fetma]. Lakartidningen 2001;98(15):1802-3.
103. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes, Obesity and Metabolism 2003;5(3):195-201.
104. Bode B, DeFronzo R, Bergenstal R, Kushner R, Lewin A, Skjoth T V, et al. Effect of liraglutide 3.0/1.8 mg on body weight and cardiometabolic risk factors in overweight/obese adults with type 2 diabetes: SCALE diabetes randomised, double-blind, 56-week trial. Diabetologia 2014;57(Suppl1):S83. [EMBASE: 71594831]
105. Davies MJ, DeFronzo RA, Bergenstal RM, Bode BW, Kushner R, Noctor M, et al. Liraglutide 3.0mg results in significant weight loss and improvements in cardiometabolic risk factors compared with liraglutide 1.8mg or placebo: A randomised, double-blind, 56 week trial in overweight/obese adults with Type 2 diabetes (SCALE diabetes). Diabetic Medicine 2015;32:72. [EMBASE: 71821008]
106. Hollander P, Aronne L, Klein S, Niswender K, Jensen CB, Woo V, et al. Diet-induced weight loss and subsequent addition of liraglutide 3.0 mg reduces impaired fasting glucose in overweight/obese adults in the scaleTM maintenance 56-week randomised trial. Journal of Diabetes 2013;5:124. [EMBASE: 71034943]
107. Fujioka K, Wilding JPH, Astrup A, Greenway F, Halpern A, Krempf M, et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight/obese adults: The SCALE obesity and prediabetes trial. Diabetologia 2014;57(Suppl1):S368-9. [EMBASE: 71595554]
108. Krempf M, Astrup A, Le Roux C, Fujioka K, Greenway F, Halpern A, et al. Liraglutide 3.0 mg reduces body weight and improves cardiometabolic risk factors in overweight/obese adults: The SCALE obesity and prediabetes randomised trial. Diabetologia 2014;57(Suppl1):S368. [EMBASE: 71595553]
109. Proietto J, Le Roux CW, Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, et al. Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE obesity and prediabetes, a randomised, double-blind and placebo-controlled trial. Obesity Research and Clinical Practice 2014;8:117. [EMBASE: 71741424]
110. Wilding J, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: The scaleTM obesity and prediabetes, a randomised, double-blind and placebo-controlled trial. Obesity Facts 2014;7:15. [EMBASE: 71497901]
111. Wilding J, Lau D, Astrup A, Fujioka K, Greenway F, Krempf M, et al. Safety and tolerability of liraglutide 3.0mg following 56 weeks of randomised treatment in overweight and obese adults: SCALE obesity and pre-diabetes trial. Diabetic Medicine 2015;32:70. [EMBASE: 71821004]
112. Wittert G, Le Roux CW, Astrup A, Fujioka K, Greenway F, Halpern A, et al. Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial. Obesity Research and Clinical Practice 2014;8:118. [EMBASE: 71742425]
113. Collier A, Blackman A, Foster G, Zammit G, Rosenberg R, Wadden T, et al. Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: Scale sleep apnoea trial. Thorax 2014;69:A16-7. [EMBASE: 71688686]
114. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat. Diabetes and Metabolism 2002;28(6 I):437-45.
115. James P, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, et al. Effects on mortality and morbidity in overweight/obese subjects: The sibutramine cardiovascular outcomes (SCOUT) trial. Journal of the American College of Cardiology 2010;Conference: American College of Cardiology's 59th Annual Scientific Session and i2 Summit: Innovation in Intervention Atlanta, GA United States. Conference Start: 20100314 Conference End: 20100316. Conference Publication:(var.pagings). 55 (10 SUPPL 1):A141.E1326.
116. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England Journal of Medicine 2010;363(10):905-17.
117. Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, et al. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of Cardiovascular Pharmacology 2008;52(5):393-402.
118. Seimon R, Espinoza D, Ivers L, Gebski V, Finer N, Legler U, et al. Changes in body weight and blood pressure: Paradoxical outcome events in overweight and obese subjects with cardiovascular disease. Obesity Reviews 2014;15:173. [EMBASE: 71516191]
119. Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N, Legler UF, et al. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International Journal of Obesity 2014;38:1165-71. [PUBMED: 24406481]
120. Garvey WT, Najarian T, Peterson CA. Significant weight loss with controlled-release phentermine/topiramate (PHEN/TPM CR) is associated with significant reductions in use of concomitant medications for cardiometabolic diseases over 108 weeks. Obesity 2011;19:S176. [EMBASE: 70680319]
121. Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care 2014;37:912-21. [PUBMED: 24103901]
122. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. American Journal of Clinical Nutrition 2012;95:297-308. [EMBASE: 2012064424]
123. Klein S, Najarian T, Troupin B, Day WW. Weight loss (WL) with low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR) correlates with improvements in liver function in overweight/obese adults with elevated alanine aminotransferase (ALT). Obesity 2011;19:S177. [EMBASE: 70680321]
124. Toplak H, Rossner S, Garvey WT, Troupin B, Bowden CH. Long-term weight loss with controlled-release phentermine/topiramate reverses metabolic syndrome and improves associated traits. Diabetologia 2011;54:S370. [EMBASE: 70563050]
125. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group [see comment]. The Lancet 1998;352(9123):167-72.
126. Starling RD, Liu X, Sullivan DH. Influence of sibutramine on energy expenditure in African American women. Obesity Research 2001;9(4):251-6. [PUBMED: 11331428]
127. Suyog J, Milind P, Karuna R. Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients. International Journal of Pharma and Bio Sciences 2011;2(1):179-87.
128. Svendsen M, Rissanen A, Richelsen B, Rossner S, Hansson F, Tonstad S. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial. Obesity (Silver Spring) 2008;16(2):327-33.
129. Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes, Obesity & Metabolism 2005;7(3):254-62.
130. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism 2003;5(5):338-44.
131. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. American Journal of Clinical Nutrition 2004;79(1):22-30.
132. Triay J, Mundi M, Klein S, Toledo F G, Smith S R, Abu-Lebdeh H, et al. Does rimonabant independently affect free fatty acid and glucose metabolism?. JCEM 2012;97(3):819-27.
133. Tunyan AM. Cardioprotective effects of antihypertensive therapy with orlistat treatment and hypocaloric diet in combination in obese hypertensive patients. Circulation 2007;115(8):E248. [CENTRAL: CN-00868400]
134. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study [see comment] [erratum appears in Lancet 2005 Jul 30-Aug 5;366(9483):370]. The Lancet 2005;365(9468):1389-97.
135. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. European Heart Journal 2008;29(14):1761-71.
136. Wang YJ, Liu C, Liu YM. Orlistat for adjuvant treatment of fatty type 2 diabetes mellitus in 32 patients. Zhongguo xin yao yu lin chuang za zhi [Chinese journal of new drugs and clinical remedies] 2003;22(11):651-3.
137. Winslow DH, Bowden CH, DiDonato K, McCullough PA. The effects of once-daily 15mg phentermine plus 92mg topiramate extended-release (PHEN/TPM ER) on cardiometabolic endpoints in obese patients with obstructive sleep apnea. Sleep 2013;36:A297. [EMBASE: 71513682]
138. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012;35:1529-39. [PUBMED: 23115402]
139. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286(11):1331-9.
140. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. American Heart Journal 2002;144(3):508-15.
141. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. Journal of Hypertension 1998;16(12 Pt 2):2013-7.
142. TM) trial: Rationale and study design. Diabetic Medicine 2012;29:68. [EMBASE: 70695949]
143. TM) trial: Rationale and study design. Diabetes 2011;60:A612-3. [EMBASE: 70630008]
144. Consoli A, Bergenstal R, Daniels G, Mann J, Nissen S, Pocock S, et al. Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (leader) trial: Rationale and study design. High Blood Pressure and Cardiovascular Prevention 2012;19(2):104. [EMBASE: 713987964]
145. Mannucci E, Bergenstal R, Daniels G, Mann J, Nissen S, Zinman B, et al. Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) Trial: Rationale and study design. Italian Journal of Medicine 2012;6(1, Suppl 1):86. [EMBASE: 70799751]
146. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal 2013;166:823-30. [EMBASE: 2013691152]
147. Abbott Germany. Theobald F. Press release: [Abbott setzt Vertrieb seiner Medikamente mit dem Wirkstoff Sibutramin zur Behandlung von Adipositas in den Ländern der Europäischen Union aus.] 2010. Available from: http://www.abbott.de/press/show/e7340/e19695/e18095/Sibutramin_210110_Theobald_de.pdf (cited 14 January 2013).
148. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2015;100(2):342-62. [PUBMED: 25590212]
149. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring, Md.) 2013;21(11):2163-71. [PUBMED: 24136928]
150. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005;45(6):1035-41. [PUBMED: 15897373]
151. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Design, Development and Therapy 2014;8:1419-27. [PUBMED: 25258511]
152. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obesity Reviews: an official journal of the International Association for the Study of Obesity 2013;14(5):383-92. [PUBMED: 23331711]
153. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Canadian Journal of Cardiology 2014;30(5):485-501. [PUBMED: 24786438]
154. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet 2010;376(9740):517-23. [PUBMED: 20709233]
155. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes, Obesity & Metabolism 2005;7(1):47-55. [PUBMED: 15642075]
156. European Medicines Agency (EMA). Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014779.pdf (updated 23 October 2008; cited 17 December 2012).
157. European Medicines Agency (EMA). Press Release - The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500014774.pdf (updated 23 October 2008; cited 17 December 2012).
158. European Medicines Agency (EMA). Public Statement on Acomplia (rimonabant) - Withdrawal of the marketing authorisation in the European Union. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf (updated 30 January 2009; cited 17 December 2012).
159. European Medicines Agency (EMA). Victoza (liraglutide) - EPAR - Summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001026/WC500050013.pdf (updated 8 July 2009; cited 17 December 2012).
160. European Medicines Agency (EMA). Press Release - European Medicines Agency recommends suspension of marketing authorisations for sibutramine. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf (updated 21 January 2010; cited 17 December 2012).
161. European Medicines Agency (EMA). Questions and answers on the suspension of medicines containing sibutramine. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Sibutramine_107/WC500094238.pdf (updated 6 August 2010; cited 17 December 2012).
162. European Medicines Agency (EMA). Questions and answers on the withdrawal of the marketing authorisation application for Belviq (lorcaserin). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143811.pdf (updated 31 May 2013; cited 20 July 2015).
163. European Medicines Agency (EMA). Withdrawal assessment report for Belviq. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/human/002597/WC500148196.pdf (updated 20 August 2013; cited 20 July 2015).
164. European Medicines Agency (EMA). Questions and answers on the refusal of the marketing authorisation for Qsiva (phentermine/topiramate). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215.pdf (updated 22 February 2013; cited 20 July 2015).
165. European Medicines Agency (EMA). Scientific conclusions and grounds for refusal of the marketing authorisation for Qsiva (13 June 2013). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002350/human_med_001607.jsp&mid=WC0b01ac058001d124# (updated 13 June 2013; cited 20 July 2015).
166. European Medicines Agency (EMA). Mysimba (naltrexone/bupropion) - EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003687/WC500185583.pdf (updated 15 April 2015; cited 20 July 2015).
167. European Medicines Agency (EMA). Saxenda (liraglutide) - EPAR summary for the public. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003780/WC500185789.pdf (updated 16 April 2015; cited 20 July 2015).
168. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure 2014;23(1):3-16. [PUBMED: 24359485]
169. US Food, Drug Administration. Egan AG. Colman EG. FDA Rimonabant Briefing Document. Endocrine and Metabolic Drugs Advisory Committee. 2007. Available from: http://www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf (updated 13 June 2007; cited 18 December 2012).
170. US Food, Drug Administration (FDA). Recommendation on a regulatory decision for Meridia (sibutramine). Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM228795.pdf (updated 7 October 2010; cited 18 December 2012).
171. US Food, Drug Administration (FDA). FDA News Release: Abbott Laboratories agrees to withdraw its obesity drug Meridia. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm228812.htm (updated 8 October 2010; cited 18 December 2012).
172. US Food, Drug Administration (FDA). Victoza (Liraglutide (rDNA)) - Approval letter. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022341s000approv.pdf (updated 25 January 2010; cited 20 July 2015).
173. US Food, Drug Administration (FDA). Qsymia (phentermine and topiramate extended-release) - Approval letter. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000Approv.pdf (updated 17 July 2012; cited 20 July 2015).
174. US Food, Drug Administration (FDA). Contrave (naltrexone hydrochloride/bupropion hydrochloride) - Approval letter. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000Approv.pdf (updated 10 September 2014; cited 20 July 2015).
175. US Food, Drug Administration (FDA). Saxenda (liraglutide) - Approval letter. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/206321Orig1s000ltr.pdf (updated 23 December 2014; cited 20 July 2015).
176. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. The Journal of Clinical Endocrinology and Metabolism 2011;96(10):3067-77. [PUBMED: 21795446]
177. Higgins JPT, Green S(editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
178. Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Archives of Internal Medicine 2008;168(6):571-80. [PUBMED: 18362248]
179. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension [Nutzenbewertung nichtmedikamentöser Behandlungsstrategien bei Patienten mit Bluthochdruck: A-Gewichtsreduktion]. Available from: http://iqwig.de/download/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 2006:19-119.
180. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-20. [PUBMED: 24352797]
181. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obesity Research 2003;11(9):1116-23. [PUBMED: 12972682]
182. NEJM Journal Watch. FDA reminds clinicians of liraglutide's risks for pancreatitis and cancer. Available from: http://www.jwatch.org/fw201106140000002/2011/06/14/fda-reminds-clinicians-liraglutides-risks (cited 20 July 2015).
183. National Institute for Health and Clinical Excellence (NICE). Hypertension - The clinical management of primary hypertension in adults; Clinical Guideline 127. 2011. Available from: http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf (updated August 2011; cited 18 December 2012).
184. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. The Lancet 2007;369(9555):71-7. [PUBMED: 17208644]
185. Moher D, Liberati A, Tetzlaff J, Altman D G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9, W64. [PUBMED: 19622511]
186. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9. [PUBMED: 18006966]
187. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Molecular and Cellular Endocrinology 2009;297(1-2):137-40. [PUBMED: 19041364]
188. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. The Lancet 2006;368(9548):1660-72. [PUBMED: 17098084]
189. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD006423.pub2; PUBMED: 21975753]
190. Taylor JR, Dietrich E, Powell J. Lorcaserin for weight management. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013;6:209-16. [PUBMED: 23788837]
191. World Health Organization. Khatib OMN, El-Guindy MS (editors). Clinical guidelines for the management of hypertension. WHO EMRO Technical Publication Series 29. 2005. Available from: http://www.emro.who.int/dsaf/dsa234.pdf (cited 14 January 2013).
192. World Health Organization. World Health Day 2013 - A global brief on hypertension. 2013. Available from: http://www.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf (cited 20 July 2015).
193. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311(1):74-86. [PUBMED: 24231879]
194. Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes 2015;7(3):329-39. [PUBMED: 25043423]
195. Siebenhofer A, Horvath K, Jeitler K, Berghold A, Stich A K, Matyas E, et al. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007654.pub2; PUBMED: 19588440]
196. Siebenhofer A, Jeitler K, Horvath K, Berghold A, Siering U, Semlitsch T. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD007654.pub3; PUBMED: 23543553]